FDA clears Zyn nicotine pouches as lower-risk alternative to smoking
TL;DR Summary
The FDA said it would allow Philip Morris to market Zyn nicotine pouches as a lower-risk alternative to cigarettes, approving 20 variants with claims that using Zyn reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. Regulators see potential population-health benefits, while scientists caution about risks to new users and youth. Philip Morris has been expanding Zyn sales and has lobbied for clearer, faster FDA approvals.
- FDA allows Philip Morris to market Zyn as less harmful than cigarettes Yahoo
- Some ZYN nicotine pouches can be sold as safer than cigarettes, FDA says NBC News
- Zyn gets FDA approval to claim lower risk than cigarettes USA Today
- FDA allows ZYN pouches to market relative health benefits Axios
- FDA lets Philip Morris market Zyn nicotine pouches as less harmful than cigarettes CNBC
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
43 min
vs 44 min read
Condensed
99%
8,664 → 72 words
Want the full story? Read the original article
Read on Yahoo